Valo is a technology company built to transform the drug discovery and development process using human-centric data and AI-powered computation. Valo is fully integrating human-centric data across the entire drug development lifecycle into a single unified architecture, thereby accelerating the discovery and development of life-changing drugs while simultaneously reducing the cost, time, and failure rate. The company’s Opal Computational Platform™ consists of an integrated set of capabilities designed to transform data into valuable insights that may accelerate discoveries and enable Valo to advance a robust pipeline of programs across cardiovascular metabolic renal, oncology, and neurodegenerative disease. 

PSP Investments

Longevity Vision Fund

Koch Disruptive Technologies

Atinum Investment

HBM Healthcare Investments AG

E Squared Capital Management

Invus

Flagship Pioneering

Mirae Asset Capital

Valo Health

DNSSEC

Content Delivery Network

Amazon

Cloudflare CDN

DMARC

IPv6

Cloudflare Hosting

Cloudflare

Microsoft Azure DNS

Chief People Officer

Cissy Young, Phd

President, Head of Therapeutics and Technology

Dave Morris

Founder and CEO

David Berry

Senior Principal Scientist

Eric Lazear

Chief Strategy Officer

Moni Miyashita

Co-Founder and CTO

Tristan F.

VP IT & Portfolio Management

Craig Conlon

Vice President, Chief Counsel, Intellectual Property

Jennifer Burdman

Vice President of Finance & Accounting

John Applegate

David Epstein

Brett R. Blackman

Chief Innovation Officer

Graeme Bell

EVP & CFO

Ilya Rekhter

Investor

Guido Lanza

VP of Innovation

New England Companies With More Than 10 Employees (Top 10K)

Health Care Companies With Less Than $500M in Revenue (Top 10K)

Information Technology Companies With More Than $1M in Revenue (Top 10K)

Health Care Companies With Fewer Than 1000 Employees (Top 10K)

Valo Health, Inc (Valo) is a technology company focused on utilizing large scale data and AI-driven computation to discover and develop therapeutics. Valo aims to fully integrate human-centric data across the entire drug development life cycle into a single unified architecture, thereby accelerating the discovery and development of life-changing drugs while simultaneously reducing costs, time, and failure rates. The company’s Opal Computational Platform™ is an end-to-end drug discovery and development platform with a unified architecture designed to transform data into valuable insights that may accelerate discoveries and enable Valo to advance a robust pipeline of programs, initially focused on cardiovascular metabolic renal, oncology, and neurodegenerative disease. Founded by Flagship Pioneering and headquartered in Boston, MA, Valo also has offices in Lexington, MA, and New York, NY. To learn more, visit valohealth.com.

Series C - Valo Health

Series B - Valo Health

Debt Financing - Valo Health

Series A - Valo Health

Computer and Software Services and Scientific Services

Boston

Massachusetts

United States

North America

Invertible models of cardiac function

Valo Health patents new PARP-1 inhibitors

System and method for predicting and optimizing clinical trial outcomes

Valo Health enters $2.7B pact with Novo Nordisk to develop heart drugs

Novo signs up for nearly a dozen cardiometabolic programs out of Valo Health

Novo Nordisk Turns to Flagship’s Valo Health for AI-Driven Cardio Drug R&D

Novo Nordisk, Valo Health in Drug Discovery and Development Pact

Valo Health to Participate in UBS Biotechnology Virtual Private Company Symposium

Valo Health to Participate in Upcoming Conferences and Events

An end-to-end drug discovery and development platform that integrates machine learning, tissue biology, and patient data to accelerate the discovery and development of therapeutics.

An end-to-end drug discovery and development platform that integrates human-centric data to accelerate the discovery and development of therapeutics.

An integrated AI-powered drug discovery solution that translates targets to candidate nomination, developed in collaboration with Charles River Laboratories.

An AI-powered drug discovery solution that transforms drug discovery by translating targets to candidate nomination.

Finland

Europe

India

Asia

Poland

Moldova

HTML5

Google Analytics

Vimeo

F5 NGINX

Adobe Flash

Office 365

Insitro is a company specializing in AI-powered drug discovery and development, similar to Valo. It is known for its innovative approaches in the pharmaceutical industry.

Insitro

Atomwise is a competitor of Valo, focusing on AI-powered drug discovery and development. It is recognized for its contributions to the pharmaceutical industry.

Atomwise

BERG is a key competitor of Valo, engaged in AI-driven drug discovery and development. It is a significant player in the pharmaceutical industry.

BERG

BioMap is a pioneer in AI foundation models for life sciences, focusing on understanding and predicting complex life behaviors and generating diverse proteins.

BioMap

Valo Health is a cutting-edge technology company focused on revolutionizing drug discovery and development through its Opal Computational Platform™, which combines machine learning, tissue biology, and patient data.

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general	Mar 4, 2024 1:40 PM	ee4fdc61
public peers	general
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Mar 4, 2024 1:40 PM	a3279693
company summary	general
signals	general
crunchbase trigger	general	Nov 22, 2024 7:44 AM	4e492a47
crunchbase profile	general	Nov 22, 2024 9:30 AM	7e2a0863
li profile	general	Mar 4, 2024 1:40 PM	b87edae2
translate crunchbase fundingrounds	general	Nov 22, 2024 3:53 PM	c98291fd
peers	general
news basic	general	Mar 4, 2024 1:40 PM	a462076b
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:VALOHEALTH

Valo Health